Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligufalimab + Azacitidine in Acute Myeloid Leukemia
NCT04980885Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Aug 2021
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab in acute myeloid leukemia (AML), sponsored by Akeso, Inc.. Started Aug 2021; status: active, not recruiting.
02
Drugs
ligufalimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04980885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980885.